Reuters logo
BRIEF-Poxel announces positive top line results for Imeglimin Phase 2b study in Japan for the treatment of Type 2 Diabetes
May 4, 2017 / 6:48 AM / 7 months ago

BRIEF-Poxel announces positive top line results for Imeglimin Phase 2b study in Japan for the treatment of Type 2 Diabetes

May 4 (Reuters) - Poxel Sa:

* Poxel announces positive top line results for Imeglimin Phase 2b study in Japan for the treatment of Type 2 Diabetes

* Imeglimin Phase 2b trial in 299 Japanese patients achieved statistical significance for primary and key secondary endpoints

* Imeglimin phase 3 program in Japan is anticipated to initiate in Q4 of 2017

* Japanese diabetes market is fast-growing and anticipated to reach approximately $6b by 2020

* Poxel anticipates presenting full data results of Phase 2b study in Japanese patients at scientific meetings during second half of 2017.

* Trial achieved statistical significance (p<0.0001) for its primary endpoint of glycated hemoglobin a1c reduction versus placebo in all treatment groups at 24 weeks Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below